

**DNAVISION****Contact :**

Jean-Pol Detiffe  
CEO  
+32(0)71378527

**IPSOGEN****Contact:**

Vincent Fert  
President and CEO  
+33(0) 4 91 29 30 90

---

## **DNA Vision ready to operate as European Central Diagnostic Lab for Ipsogen MapQuant Dx™ Genomic Grade test in breast cancer**

**Gosselies, Belgium, June 2nd, 2008 – DNA Vision** announced today that it will begin ISO-17025 MapQuant Dx™ Central Lab Services in Europe for Ipsogen on Affymetrix GeneChip® Systems 3000Dx2.

The Ipsogen MapQuant Dx™ Genomic Grade test in breast cancer is the very first molecular diagnostic test to accurately measure tumor grade, a consensus indicator of tumor proliferation, risk of metastasis and response to chemotherapy.

"DNA Vision is delighted of having been chosen by IPSOGEN as the first pharmacogenomic private testing laboratory to provide this innovative diagnostic expression microarray test" said Jean-Pol Detiffe, Chief Executive Officer of DNA Vision.

"We are very proud to have demonstrated the high reproducibility of this innovative test during analytical validation phase and so, we can now deliver it as diagnostic test" said Jean-François Laes, Microarray Unit Manager of DNA Vision

"This newly formalized collaboration is a further evidence of DNA Vision's involvement in the field of pharmacogenomic and personalized medicine" added Michäel Herman, Business Development Manager of DNA Vision. "Beside our direct services for physicians and patients (i.e. CYP2D6 genotyping for evaluation of tamoxifen treatment's benefit) or pharmaceutical companies (i.e. poor metabolizers screening or gene signature monitoring in clinical trials), this new partnership, which will call for further ones with other partners, demonstrates that DNA Vision is probably the central diagnostic lab of choice in the heart of Europe".

## **About MapQuant Dx™ Genomic Grade**

### ***Clinical Validation***

MapQuant Dx™ Genomic Grade measures the Genomic Grade index, a gene expression index discovered by oncology researchers at the Bordet Institute (Brussels, Belgium) and ISREC (Lausanne, Switzerland), two leading European cancer research institutes. In their seminal paper published in 2006 in the Journal of the National Cancer Institute (1), Pr. Sotiriou & colleagues showed that the grade, as measured today and since 1890 by histological examination of breast tumor sections under a microscope, could not describe the proliferation ability of 30 to 60 % of tumors. By contrast, the Genomic Grade index could capture proliferation in most tumors and showed superior prognostic and classification value over conventional grading methods. These findings have been validated in more than 1,100 patients, including a second study published last year in the Journal of Clinical Oncology (2). In 2008, 3 studies from the MD Anderson Cancer Center (MDACC) validated that high Genomic Grade index was predictive for benefit from chemotherapy (3).

### ***Regulatory***

MapQuant Dx™ Genomic Grade is made available for diagnostic use in Europe by Ipsogen through its MapQuant Dx™ testing solution including: MapQuant Dx™ Path Kit, CE-marked, ensuring easy sampling, RNA-preservation and shipping at ambient temperature; ISO-17025 MapQuant Dx™ Lab Services performed by DNAVision SA (Gosselies, Belgium) on GeneChip® Systems 3000Dx2 (GCS3000Dx2) of Affymetrix, the first microarray instrumentation system for molecular diagnostic laboratories, ensuring highly reproducible sample processing; MapQuant Dx™ CE-compliant software, ensuring highly reliable quality controls, data processing and Genomic Grade index computation. MapQuant Dx™ testing solution is developed under the innovation support program of the French Health Products Safety Agency (Afssaps).

### **About IPSOGEN**

Ipsogen is a cancer profiler that develops and markets molecular diagnostic assays designed to map diseases and guide patients and clinicians decisions along the complex therapeutic path.

With more than 60 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that has been inaccessible until now. Ipsogen is also a partner of choice for biopharmaceutical companies committed to revolutionary theranostics.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly-skilled multidisciplinary team in France and the US, Ipsogen is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society in general.

Ipsogen employed 40 people as of April 30,2008. Its headquarters are located in Marseille, France. The company also has a subsidiary, Ipsogen Inc., in New Haven, Connecticut, USA.

### **About DNAVISION**

DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services. DNAVision offers the powerful combination of different technologies in expression profiling, SNP genotyping and sequencing in a high quality environment. DNAVision is a spin-off of Free University of Brussels and Institute of Pathology and Genetics. DNAVision is the first full-service pharmacogenomic laboratory to be ISO17025 accredited, GLP certified and CLIA. DNAVision is a

spin-off of University of Brussels and Institute of Pathology and Genetics. More information on DNAVision's service portfolio can be found on [www.dnavision.be](http://www.dnavision.be)

More information on DNAVision's service portfolio can be found on [www.dnavision.be](http://www.dnavision.be)

NOTE: Ipsogen and Ipsogen Logo are registered trademarks owned by Ipsogen. DNAVision and DNAVision Logo are registered trademarks owned by DNAVision.